Serum Evaluation of Interleukin 6 in Ovarian Cancer Patients
- 1 July 1997
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 66 (1) , 27-30
- https://doi.org/10.1006/gyno.1997.4726
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet countsCancer, 1995
- Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivoCancer Immunology, Immunotherapy, 1994
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced CancerJournal of Immunotherapy, 1994
- Subcutaneously Administered Recombinant Interferon-γ in HumansJournal of Immunotherapy, 1994
- Autocrine and paracrine functions of cytokines in malignant lymphomasBiomedicine & Pharmacotherapy, 1994
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991
- Antitumor activity of recombinant interleukin 6 in mice.The Journal of Experimental Medicine, 1990
- Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.The Journal of Experimental Medicine, 1989
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982